Arrowhead Pharmaceuticals, Inc.
ARWRHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeArrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Valued at $10.97B, ARWR is a large-cap name in its sector. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials.
Market Cap
$10.97B
Beta
1.29
P/E (TTM)
—
P/E (Fwd)
-17.95
EPS (TTM)
$-2.27
EPS (Fwd)
$-4.34
ROE
-42.4%
ROA
-7.2%
Cash
$1.78B
Total Debt
$1.38B
Free CF
-$46.1M
52W Change
375.1%
Annual Financials
Cash vs Debt
With $1.78B in cash and $1.38B in debt, ARWR maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$46.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -42.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $243.2M to $829.4M.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Arrowhead Pharmaceuticals, Inc. and its sector.